Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business In Brief

Executive Summary

AMAG's Feraheme gets CMS Q-codes: AMAG Pharmaceuticals' novel I.V. anemia therapyFeraheme (ferumoxytol) brought in about $3 million in third-quarter sales, largely due to launch pilots. But non-dialysis chronic kidney disease providers are buying significantly more product than dialysis organizations, execs said during an Oct. 29 earnings call. "This does not mean that our sales will continue to be weighted towards non-dialysis CKD, but it's indicative of the differences in the sales cycle between the two segments," said Timothy Healey, Senior VP-Commercial Operations. Before switching products, dialysis organizations consider how a drug performs, how it will affect work flow and contractual incentives - reimbursement is crucial since that is how the dialysis businesses get paid. In a positive nod, CMS assigned Feraheme two unique temporary Medicare Q-codes for dialysis and pre-dialysis patients just a few months after the drug gained FDA approval in June (1"The Pink Sheet," July 6, 2009). The Q-codes, effective Jan. 1 2010, will speed reimbursement since they are product-specific and don't require a claim-by-claim manual review

You may also be interested in...



The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

Fresh Off Tysabri Court Win, Biogen Idec Makes A Hostile Bid For Facet Biotech

Spun out of PDL Biopharma late last year, Facet already has a partnership with Biogen for oncology and multiple sclerosis programs.

Related Content

Topics

UsernamePublicRestriction

Register

PS051640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel